Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Synairgen 's new fibrosis collaboration terms will free it to work in other areas

The new terms give it the opportunity to benefit from a partnership across a whole range of fibrosis-focused treatments
IPF chart
Synairgen's interest is much wider than just IPF under new terms

Synairgen PLC’s (LON:SNG) £5m payment from Pharmaxis will boost cash sufficiently to fund fully the SNG001 Phase IIa trial of inhaled interferon in COPD, says broker finncap.

As well as the cash, Synairgen will also receive 17% of all partnering proceeds for Pharmaxis’ LOXL2 development pipeline in all fibrotic indications, including NASH, IPF, heart and kidney – significant areas of interest from large pharma.

READ: Synairgen shoots higher on new terms for fibrosis collaboration

The broker adds that Synairgen will also be able to explore other opportunities in which it can use its respiratory models to generate incremental value for shareholders, in the same way that it has shown for the LOXL2 programme.

The two companies have been collaborating on the development of a Lysyl Oxidase type 2 (LOXL2) inhibitor (PXS-5382) to treat lung and liver fibrosis.

Richard Marsden, Synairgen’s chief executive, said the new terms give it the opportunity to benefit from a partnership across a whole range of fibrosis-focused treatments.

“Having previously been focused toward a lung-related partnering transaction, this change in terms enables Synairgen to benefit significantly from any licence(s) in the non-lung related fibrosis arena." 

READ: Synairgen planning winter trial as it develops inhaled interferon beta drug for COPD

Under the revised terms, Pharmaxis will take on full operational responsibilities for the programme, including the ongoing Phase I trial of PXS-5382.

Pharmaxis is independently developing a second treatment to cover multiple fibrotic conditions and Marsden said it made sense to have a single point of focus in any partnering discussions. 

The Aussie firm has already negotiated one major partnership with Boehringer Ingelheim for a compound for liver complaint non-alcoholic steatohepatitis or NASH.

Marsden added: "Under the existing collaboration, Synairgen generated excellent data to support progression in the rare fibrotic lung disease idiopathic pulmonary fibrosis (IPF) and Pharmaxis has focused on the potentially larger indications of liver fibrosis (including non-alcoholic steatohepatitis (NASH)), cardiac fibrosis and kidney fibrosis.

“As we draw nearer to an optimal point for partnering the programme, it is more effective and should be more value enhancing to hand all control of the development to Pharmaxis to enable a single point of focus for multi-indication partnering discussions.”

Timetable points to mid-2018 as key point

Results from PXS-5382A's Phase I trial are scheduled for the middle of 2018, after which the aim is to find a partner to license the drug due to size of the potential market and number of indications it could address.

WATCH: Synairgen's chief hails exciting IPF data from LOXL2 inhibitor programme

“PXS-5382A is a very valuable candidate with potential applications in a number of fibrotic conditions with very substantial market opportunities,” said Marsden.

"The effect of this novel inhibitor across different model types is very exciting, with the latest supporting data suggesting that PXS-5382A can significantly reduce lung fibrosis and therefore has the potential to improve lung function in severely ill patients.”

Data from AstraZeneca trial expected

The final assessment of the Phase II trial of interferon beta should also be released at some point this year.

Last October, FTSE 100-listed AstraZeneca halted work on the Phase IIa clinical trial after it struggled to find enough hard-to-treat cases among asthma sufferers.

At the time, Synairgen said that based on the biomarker, lung function and safety data, it may be developed to treat lung diseases where viral infections are a real problem, such as chronic obstructive pulmonary disease (COPD) though first management wanted to see the data from the AZ study of asthma patients.

"We remain positive about the potential of inhaled interferon beta, particularly for patients with COPD who suffer due to respiratory viruses,” said Marsden.

“Once we have completed the data analysis, we will provide an update on the programme and our plans for future development."

View full SNG profile View Profile

Synairgen plc Timeline

Related Articles

Graphic of person pointing to different parts of the body
May 14 2018
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.
August 21 2018
The company aims to revolutionise the HPA production process, eschewing the laborious bauxite-sourced method.
scientist in lab
September 07 2018
Normally, patients have to wait until regulators have approved a drug before they get access to it, but up to 500 lupus sufferers will receive Lupuzor as part of a Managed Access Programme

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use